Literature DB >> 22446032

Primary hyperoxalurias: disorders of glyoxylate detoxification.

Eduardo Salido1, Angel L Pey, Rosa Rodriguez, Victor Lorenzo.   

Abstract

Glyoxylate detoxification is an important function of human peroxisomes. Glyoxylate is a highly reactive molecule, generated in the intermediary metabolism of glycine, hydroxyproline and glycolate mainly. Glyoxylate accumulation in the cytosol is readily transformed by lactate dehydrogenase into oxalate, a dicarboxylic acid that cannot be metabolized by mammals and forms tissue-damaging calcium oxalate crystals. Alanine-glyoxylate aminotransferase, a peroxisomal enzyme in humans, converts glyoxylate into glycine, playing a central role in glyoxylate detoxification. Cytosolic and mitochondrial glyoxylate reductase also contributes to limit oxalate production from glyoxylate. Mitochondrial hydroxyoxoglutarate aldolase is an important enzyme of hydroxyproline metabolism. Genetic defect of any of these enzymes of glyoxylate metabolism results in primary hyperoxalurias, severe human diseases in which toxic levels of oxalate are produced by the liver, resulting in progressive renal damage. Significant advances in the pathophysiology of primary hyperoxalurias have led to better diagnosis and treatment of these patients, but current treatment relies mainly on organ transplantation. It is reasonable to expect that recent advances in the understanding of the molecular mechanisms of disease will result into better targeted therapeutic options in the future.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446032     DOI: 10.1016/j.bbadis.2012.03.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  44 in total

1.  Glyoxylate detoxification is an essential function of malate synthase required for carbon assimilation in Mycobacterium tuberculosis.

Authors:  Susan Puckett; Carolina Trujillo; Zhe Wang; Hyungjin Eoh; Thomas R Ioerger; Inna Krieger; James Sacchettini; Dirk Schnappinger; Kyu Y Rhee; Sabine Ehrt
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-06       Impact factor: 11.205

Review 2.  Primary hyperoxalurias: diagnosis and treatment.

Authors:  Efrat Ben-Shalom; Yaacov Frishberg
Journal:  Pediatr Nephrol       Date:  2014-12-18       Impact factor: 3.714

Review 3.  Molecular therapy of primary hyperoxaluria.

Authors:  Cristina Martin-Higueras; Armando Torres; Eduardo Salido
Journal:  J Inherit Metab Dis       Date:  2017-04-19       Impact factor: 4.982

Review 4.  Genetic Infiltrative Cardiomyopathies.

Authors:  Mary E Sweet; Luisa Mestroni; Matthew R G Taylor
Journal:  Heart Fail Clin       Date:  2018-04       Impact factor: 3.179

5.  Human MiR-4660 regulates the expression of alanine-glyoxylate aminotransferase and may be a biomarker for idiopathic oxalosis.

Authors:  Xin Tu; Yuanyuan Zhao; Qianqian Li; Xiao Yu; Yang Yang; Shumei Shi; Zuochuan Ding; Yan Miao; Zhimiao Zou; Xinqiang Wang; Jipin Jiang; Dunfeng Du
Journal:  Clin Exp Nephrol       Date:  2019-03-09       Impact factor: 2.801

6.  Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1.

Authors:  Non Miyata; Janos Steffen; Meghan E Johnson; Sonia Fargue; Christopher J Danpure; Carla M Koehler
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-18       Impact factor: 11.205

7.  Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.

Authors:  Cristina Martin-Higueras; Sergio Luis-Lima; Eduardo Salido
Journal:  Mol Ther       Date:  2015-12-22       Impact factor: 11.454

8.  Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.

Authors:  Candice B Summitt; Lynnette C Johnson; Thomas J Jönsson; Derek Parsonage; Ross P Holmes; W Todd Lowther
Journal:  Biochem J       Date:  2015-03-01       Impact factor: 3.857

9.  Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.

Authors:  Fang Zhao; Eric J Bergstralh; Ramila A Mehta; Lisa E Vaughan; Julie B Olson; Barbara M Seide; Alicia M Meek; Andrea G Cogal; John C Lieske; Dawn S Milliner
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-10       Impact factor: 8.237

10.  A novel mutation in the AGXT gene causing primary hyperoxaluria type I: genotype-phenotype correlation.

Authors:  Saoussen M'Dimegh; Cécile Aquaviva-Bourdain; Asma Omezzine; Ibtihel M'Barek; Geneviéve Souche; Dorsaf Zellama; Kamel Abidi; Abdelattif Achour; Tahar Gargah; Saoussen Abroug; Ali Bouslama
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.